Amyloid fibrillogenesis: Themes and variations

Current Opinion in Structural Biology

Volumn 10, Issue 1, 2000, Pages 60-68

  Rochet, Jean Christophe ^a   Lansbury Jr , Peter T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GELSOLIN; GLOBULAR PROTEIN; TAU PROTEIN;

FIBER; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; REVIEW;

EID: 0033977086     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(99)00049-4     Document Type: Review

References (77)

1. Glenner G.G. Amyloid deposits and amyloidosis. The β-fibrilloses (first of two parts). N Engl J Med. 302:1980;1283-1292.
2. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem Sci. 24:1999;329-332.
3. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol. 8:1998;101-106.
4. Lansbury P.T. Jr. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA. 96:1999;3342-3344. This review contrasts fibrillogenesis with the folding of a typical soluble protein. Amyloid fibril formation involves the self-assembly of partially structured intermediates, which are generally avoided during normal protein folding. Evidence is provided to suggest that fibrillization intermediates, rather than mature fibrils, may be associated with disease.
5. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
6. Teplow D.B. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid: Int J Exp Clin Invest. 5:1998;121-142.
7. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
8. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med. 4:1998;1318-1320. Wild-type α-synuclein and the A53T and A30P mutants form fibrils in vitro that are similar in length and morphology to α-synuclein-containing fibrils isolated from cortical Lewy bodies. The authors describe spherical species and thin filaments, which may be intermediates of the fibrillization pathway.
9. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M-Y. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem. 274:1999;7619-7622.
10. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P.et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem. 274:1999;9843-9846.
11. Sunde M., Blake C. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem. 50:1997;123-159.
12. Eanes E.D., Glenner G.G. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 16:1968;673-677.
13. Jackson G.S., Hosszu L.L., Power A., Hill A.F., Kenney J., Saibil H., Craven C.J., Waltho J.P., Clarke A.R., Collinge J. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science. 283:1999;1935-1937.
14. Liu J.J., Lindquist S. Oligopeptide-repeat expansions modulate 'protein-only' inheritance in yeast. Nature. 400:1999;573-576.
15. Taylor K.L., Cheng N., Williams R.W., Steven A.C., Wickner R.B. Prion domain initiation of amyloid formation in vitro from native Ure2p. Science. 283:1999;1339-1343.
16. Thual C., Komar A.A., Bousset L., Fernandez-Bellot E., Cullin C., Melki R. Structural characterization of Saccharomyces cerevisiae prion-like protein Ure2. J Biol Chem. 274:1999;13666-13674.
17. Kelly J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol. 6:1996;11-17.
18. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem. 50:1997;183-242.
19. Canet D., Sunde M., Last A.M., Miranker A., Spencer A., Robinson C.V., Dobson C.M. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry. 38:1999;6419-6427. This report outlines kinetic analyses of the folding and unfolding of two amyloidogenic variants of lysozyme. The authors used the well-characterized folding pathway of the wild-type protein to infer precise structural consequences for each mutation. The results suggest that the equilibrium concentration of partially unfolded conformers is critical for initiating fibrillization.
20. Raffen R., Dieckman L.J., Szpunar M., Wunschl C., Pokkuluri P.R., Dave P., Stevens P.W., Cai X., Schiffer M., Stevens F.J. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8:1999;509-517.
21. Schuler B., Rachel R., Seckler R. Formation of fibrous aggregates from a non-native intermediate: the isolated P22 tailspike β-helix domain. J Biol Chem. 274:1999;18589-18596. The P22 tailspike β-helix domain forms amyloid fibrils under partially denaturing conditions. The results of equilibrium and kinetic folding studies imply that the fibrillogenic conformer retains substantial secondary structure while exposing a hydrophobic surface.
22. Groß M., Wilkins D.K., Pitkeathly M.C., Chung E.W., Higham C., Clark A., Dobson C.M. Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB. Protein Sci. 8:1999;1350-1357.
23. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA. 96:1999;3590-3594. Acylphosphatase is shown to be amyloidogenic under partially denaturing conditions. Fibrillogenesis involves the conversion of α helix to β sheet and proceeds via an intermediate protofilament. The results are of broad importance, as they suggest that most proteins should fibrillize in an environment that simultaneously favors hydrogen bonding and the exposure of hydrophobic patches.
24. Damaschun G., Damaschun H., Gast K., Zirwer D. Proteins can adopt totally different folded conformations. J Mol Biol. 291:1999;715-725. A collapsed state of phosphoglycerate kinase, which contains substantial α helix and β sheet, is populated under partially denaturing conditions that favor amyloid fibril formation. Self-assembly is associated with a net increase in β sheet. The authors demonstrate the power of dynamic light scattering to monitor the growth of aggregates during fibrillization.
25. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., Teplow D.B. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 274:1999;25945-25952. The authors provide compelling evidence to support the premise that amyloid β-peptide (Aβ40) protofibrils are on-pathway intermediates. The protofibrils, isolated by size-exclusion chromatography, consist primarily of β sheet, but also contain a minor α-helical component. The authors show, for the first time, that Aβ40 protofibrils alter the metabolism of cultured neurons.
26. Kayed R., Bernhagen J., Greenfield N., Sweimeh K., Brunner H., Voelter W., Kapurniotu A. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J Mol Biol. 287:1999;781-796. The authors have carried out a thorough analysis of the structural changes associated with the seeded and unseeded fibrillization of islet amyloid polypeptide (IAPP). The protein undergoes similar transitions and ultimately forms fibrils at 45°C or in the presence of 4.25 M guanidine hydrochloride. The results suggest that a partially structured, oligomeric intermediate is populated during fibrillogenesis.
27. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:1996;13709-13715.
28. Schweers O., Schonbrunn-Hanebeck E., Marx A., Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for β-structure. J Biol Chem. 269:1994;24290-24297.
29. Ratnaswamy G., Koepf E., Bekele H., Yin H., Kelly J.W. The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem Biol. 6:1999;293-304. A 71-residue fragment of wild-type or mutant gelsolin forms amyloid fibrils in vitro, but only at acidic pH. The authors hypothesize that the fibrillization of the gelsolin fragment in vivo occurs in an acidic organelle. The results indicate that the release of an amyloidogenic peptide via proteolysis is not always sufficient to trigger self-assembly into fibrils. This paper also provides a useful discussion of differences in the mechanisms of fibrillization between initially folded and unfolded proteins.
30. Vidal R., Frangione B., Rostagno A., Mead S., Revesz T., Plant G., Ghiso J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 399:1999;776-781.
31. Lansbury P.T. Jr., Kosik K.S. Neurodegeneration: new clues on inclusions. Chem Biol. 1999;. in press.
32. Häggqvist B., Näslund J., Sletten K., Westermark G.T., Mucchiano G., Tjernberg L.O., Nordstedt C., Engström U., Westermark P. Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci USA. 96:1999;8669-8674.
33. Cerini C., Peyrot V., Garnier C., Duplan L., Veesler S., Le Caer J-P., Bernard J-P., Bouteille H., Michel R., Vazi A.et al. Biophysical characterization of lithostathine. J Biol Chem. 274:1999;22266-22274. The fibrillization of lithostathine is pH-dependent and requires limited proteolysis. The authors demonstrate via quasi-elastic light scattering that aggregates of various sizes form prior to fibrillogenesis.
34. Harper J.D., Lansbury P.T. Jr. Models, of amyloid seeding in Alzheimer's, disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 66:1997;385-407.
35. Lansbury P.T. Jr. Structural, neurology: are seeds at the root of neuronal degeneration? Neuron. 19:1997;1151-1154.
36. Wood S.J., Wypych J., Steavenson S., Louis J-C., Citron M., Biere A.L. α-Synuclein fibrillogenesis is nucleation-dependent. J Biol Chem. 274:1999;19509-19512.
37. Friedhoff P., von Bergen M., Mandelkow E-M., Davies P., Mandelkow E. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci USA. 95:1998;15712-15717. The fibrillization of tau in vitro involves the formation of a nucleus of four to seven tau dimers. The authors demonstrate how kinetic analyses can complement biophysical measurements in providing useful structural information about prefibrillar nuclei.
38. Scherzinger E., Sittler A., Schweiger K., Heiser V., Lurz R., Hasenbank R., Bates G.P., Lehrach H., Wanker E.E. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA. 96:1999;4604-4609. The authors demonstrate that a proteolytic fragment derived from GST-huntingtin undergoes nucleation-dependent fibrillization. The results of this study account for two key properties of the polyglutamine neurodegenerative diseases, namely the glutamine-repeat threshold and the inverse relationship between the number of repeats and the age of disease onset.
39. Kusumoto Y., Lomakin A., Teplow D.B., Benedek G.B. Temperature dependence of amyloid β-protein fibrillization. Proc Natl Acad Sci USA. 95:1998;12277-12282.
40. Tseng B.P., Esler W.P., Clish C.B., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., Lee J.P., Maggio J.E. Deposition of monomeric, not oligomeric, Aβ mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry. 38:1999;10424-10431.
41. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol. 4:1997;119-125.
42. Harper J.D., Lieber C.M., Lansbury P.T. Jr. Atomic, force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β-protein. Chem Biol. 4:1997;951-959.
43. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 272:1997;22364-22372.
44. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 38:1999;8972-8980. The authors have carefully studied the assembly and disassembly of Aβ amyloid protofibrils using atomic force microscopy measurements. Protofibril elongation occurs via the addition of monomer and the coalescence of immature protofibrils, whereas disassembly involves the release of monomer only. The results provide valuable insight into the evolution of protofibrils during Aβ fibrillization. Also, the discussion contains a useful review of published evidence that prefibrillar intermediates may be the pathogenic species in Alzheimer's disease.
45. 1-42 fibrillogenesis. Scand J Immunol. 49:1999;219-223.
46. Blackley H.K.L., Patel N., Davies M.C., Roberts C.J., Tendler S.J.B., Wilkinson M.J., Williams P.M. Morphological development of β(1-40) amyloid fibrils. Exp Neurol. 158:1999;437-443.
47. Kowalewski T., Holtzman D.M. In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: new insights into mechanism of β-sheet formation. Proc Natl Acad Sci USA. 96:1999;3688-3693. This paper describes the use of in situ atomic force microscopy to investigate the self-assembly of Aβ42 on mica or graphite. The results indicate that the morphology of the aggregates varies with the properties of the surface. The experimental method is extremely innovative. Not only does it enable monitoring of the formation and growth of individual assemblies in real time, but it also addresses the important question of how surfaces influence amyloidogenesis.
48. Goldsbury C., Kistler J., Aebi U., Arvinte T., Cooper G.J.S. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J Mol Biol. 285:1999;33-39. The rate and polarity of growth of islet amyloid polypeptide (IAPP) protofibrils on mica have been determined by continuous atomic force microscopy (AFM) scanning. The results suggest that protofibrils deposited on a surface may not readily undergo association to form higher order fibrils. The paper underscores the usefulness of in situ AFM to monitor the evolution of individual assemblies under physiologically relevant conditions.
49. Tjernberg L.O., Pramanik A., Björling S., Thyberg P., Thyberg J., Nordstedt C., Berndt K.D., Terenius L., Rigler R. Amyloid β-peptide polymerization studied using fluorescence correlation spectroscopy. Chem Biol. 6:1999;53-62. The authors have analyzed the self-assembly of Aβ40 using fluorescence correlation spectroscopy (FCS) and electron microscopy (EM). The results suggest that mature fibrils may evolve from large amorphous aggregates formed early during fibrillogenesis. The study emphasizes that FCS is a sensitive method for identifying different types of assemblies in solution at various times during fibrillization.
50. Blake C., Serpell L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure. 4:1996;989-998.
51. Inouye H., Domingues F.S., Damas A.M., Saraiva M.J., Lundgren E., Sandgren O., Kirschner D.A. Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid: Int J Exp Clin Invest. 5:1998;163-174.
52. Jiménez J.L., Guijarro J.I., Orlova E., Zurdo J., Dobson C.M., Sunde M., Saibil H.R. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18:1999;815-821. The authors propose a detailed structural model for the SH3 domain amyloid fibril on the basis of a three-dimensional map obtained by cryo-EM. The fibril consists of two pairs of interwound protofibrils, each of which contains two stacked untwisted β sheets. The model suggests that partial unfolding and conformational rearrangements are essential for fibrillogenesis.
53. Kirschner D.A., Elliott-Bryant R., Szumowski K.E., Gonnerman W.A., Kindy M.S., Sipe J.D., Cathcart E.S. In vitro amyloid fibril formation by synthetic peptides corresponding to the amino terminus of apoSAA isoforms from amyloid-susceptible and amyloid-resistant mice. J Struct Biol. 124:1998;88-98. The authors used electron microscopy to show that serum amyloid A (SAA) peptides form polymorphic amyloid assemblies, including rod-like fibrils and twisted or untwisted ribbons. The study also demonstrates how X-ray diffraction analysis of dried peptide samples (prior to fibrillization) can be a powerful tool for predicting eventual fibrillar morphology.
54. Halverson K., Fraser P.E., Kirschner D.A., Lansbury P.T. Jr. Molecular, determinants of amyloid deposition in Alzheimer's, disease: conformational studies of synthetic β-protein fragments. Biochemistry. 29:1990;2639-2644.
55. Lansbury P.T. Jr., Costa P.R., Griffiths J.M., Simon E.J., Auger M., Halverson K.J., Kocisko D.A., Hendsch Z.S., Ashburn T.T., Spencer R.G.S.et al. Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol. 2:1995;990-998.
56. (10-35) is parallel β-sheet with residues in exact register. Proc Natl Acad Sci USA. 95:1998;13407-13412. The authors used solid-state NMR spectroscopy to demonstrate that the Aβ(10-35) fibril consists of parallel β sheet. These results, along with those of previous studies [54,55], suggest that fibrillar Aβ42 contains β sheet in both parallel and antiparallel arrangements.
57. Li L., Darden T.A., Bartolotti L., Kominos D., Pedersen L.G. An atomic model for the pleated β-sheet structure of Aβ amyloid protofilaments. Biophys J. 76:1999;2871-2878.
58. Lazo N.D., Downing D.T. Fibril formation by amyloid-β proteins may involve β-helical protofibrils. J Pept Res. 53:1999;633-640.
59. West M.W., Wang W., Patterson J., Mancias J.D., Beasley J.R., Hecht M.H. De novo amyloid proteins from designed combinatorial libraries. Proc Natl Acad Sci USA. 96:1999;11211-11216. This important work addresses the question of which amino acid sequences favor amyloid fibril formation. From studies of a combinatorial library of de novo designed proteins, it is concluded that a pattern of alternating polar and nonpolar residues is sufficient to encode proteins capable of forming amyloid-like protofilaments. This paper also provides a thoughtful discussion of the evolution of amyloidogenic sequences.
60. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport. 10:1999;717-721.
61. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 19:1999;8876-8884.
62. Goedert M., Spillantini M.G., Davies S.W. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol. 8:1998;619-632.
63. Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and α-synucleinopathies. Philos Trans R Soc Lond B Biol Sci. 354:1999;1101-1118.
64. Galvin J.E., Lee V.M., Schmidt M.L., Tu P.H., Iwatsubo T., Trojanowski J.Q. Pathobiology of the Lewy body. Adv Neurol. 80:1999;313-324.
65. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid: Int J Exp Clin Invest. 5:1998;55-66.
66. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 24:1999;58-63.
67. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron. 19:1997;1147-1150.
68. Clark A., Charge S.B., Badman M.K., MacArthur D.A., de Koning E.J. Islet amyloid polypeptide: actions and role in the pathogenesis of diabetes. Biochem Soc Trans. 24:1996;594-599.
69. Goedert M., Crowther R.A., Spillantini M.G. Tau mutations cause frontotemporal dementias. Neuron. 21:1998;955-958.
70. Kelly J.W., Colon W., Lai Z., Lashuel H.A., McCulloch J., McCutchen S.L., Miroy G.J., Peterson S.A. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem. 50:1997;161-181.
71. Alexandrescu A.T., Rathgeb-Szabo K. An NMR investigation of solution aggregation reactions preceding the misassembly of acid-denatured cold shock protein A into fibrils. J Mol Biol. 291:1999;1191-1206.
72. Lashuel H.A., Wurth C., Woo L., Kelly J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry. 38:1999;13560-13573. This paper describes careful studies of the effect of pH, protein concentration and temperature on the propensity of the L55P mutant of transthyretin (TTR) to dissociate to the amyloidogenic monomer and to form 'protofilaments'. Importantly, the protofilaments do not undergo self-assembly into amyloid fibrils at physiological pH. Accordingly, the authors propose that the role of the TTR protofilaments in neurodegeneration may be tested using cell culture models.
73. Lashuel H.A., Lai Z., Kelly J.W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry. 37:1998;17851-17864.
74. Ionescu-Zanetti C., Khurana R., Gillespie J.R., Petrick J.S., Trabachino L.C., Minert L.J., Carter S.A., Fink A.L. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci USA. 96:1999;13175-13179. The authors provide a detailed view of the immunoglobulin light-chain fibrillization pathway. Several oligomeric species were identified by atomic force microscopy, including filaments (height = 2.4 nm), protofibrils (height = 4.0 nm), type I fibrils (height = 8.3 nm) and type II fibrils (height = 5.9 nm). The results suggest a model in which protofibrils, type I fibrils and type II fibrils are formed by the winding of two filaments, two protofibrils and three filaments, respectively.
75. Kim S-H., Wang R., Gordon D.J., Bass J., Steiner D.F., Lynn D.G., Thinakaran G., Meredith S.C., Sisodia S.S. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci. 2:1999;984-988.
76. Yang D-S., Yip C.M., Huang T.H.J., Chakrabartty A., Fraser P.E. Manipulating the amyloid-β aggregation pathway with chemical chaperones. J Biol Chem. 274:1999;32970-32974.
77. Conway K.A., Lee S-J., Rochet J-C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration, of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA. 97:2000;571-576. The authors show, for the first time, that a mutant of α-synuclein (A30P) linked to early-onset Parkinson's disease fibrillizes less rapidly, but forms nonfibrillar oligomers more rapidly, than the wild-type protein. Several nonfibrillar assemblies, including 'spheres', 'chains' and 'rings', were isolated by gel filtration and characterized by atomic force microscopy. The results are of considerable importance, as they suggest that drugs designed to inhibit the fibrillization of α-synuclein may in fact promote the accumulation of toxic oligomeric species.